Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iradimed (IRMD) Income towards Parent Company (2016 - 2026)

Iradimed has reported Income towards Parent Company over the past 14 years, most recently at $5.8 million for Q1 2026.

  • Quarterly Income towards Parent Company rose 24.13% to $5.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.6 million through Mar 2026, up 19.34% year-over-year, with the annual reading at $22.5 million for FY2025, 16.88% up from the prior year.
  • Income towards Parent Company was $5.8 million for Q1 2026 at Iradimed, down from $6.4 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $6.4 million in Q4 2025 and troughed at $2.5 million in Q1 2022.
  • The 5-year median for Income towards Parent Company is $4.7 million (2025), against an average of $4.5 million.
  • Year-over-year, Income towards Parent Company soared 120.53% in 2022 and then dropped 15.13% in 2023.
  • A 5-year view of Income towards Parent Company shows it stood at $3.7 million in 2022, then decreased by 15.13% to $3.1 million in 2023, then soared by 65.08% to $5.1 million in 2024, then increased by 25.17% to $6.4 million in 2025, then fell by 9.69% to $5.8 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Income towards Parent Company are $5.8 million (Q1 2026), $6.4 million (Q4 2025), and $5.6 million (Q3 2025).